Estrella Immunopharma (ESLA) vs IN8bio (INAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
IN8bio (INAB) has outperformed Estrella Immunopharma (ESLA) over the past year, losing 42.7% versus a loss of 67.9%. Over five years, ESLA leads with a -95.8% price change compared with -99.2% for INAB. Estrella Immunopharma is the larger company by market cap ($18.2 million vs $13.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | INAB |
|---|---|---|
| Share price | $0.4175 | $1.38 |
| Market cap | $18.16M | $13.60M |
| 1-day change | -0.43% | -1.43% |
| YTD return | -73.24% | -41.03% |
| 1-year return | -67.88% | -42.74% |
| 5-year return | -95.77% | -99.23% |
| EPS (TTM) | $-0.25 | $-1.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $2.73 |
| 52-week low | $0.3611 | $0.88 |
| Distance from 52-week high | -86.75% | -49.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +2774.25% | +407.25% |
| Average volume | 38.27K | 59.11K |
| Shares outstanding | 43.50M | 9.86M |
| Employees | — | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed ESLA by 25.1 percentage points over the past year.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Healthcare · Biotechnology
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Healthcare · Biotechnology · 18 employees
ESLA vs INAB FAQ
Which is bigger, Estrella Immunopharma or IN8bio?
Estrella Immunopharma (ESLA) is larger, with a market capitalization of $18.16M compared with $13.60M for IN8bio (INAB).
Which stock has performed better over the past year, ESLA or INAB?
INAB returned -42.74% over the past 12 months, compared with -67.88% for ESLA (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and IN8bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.